ENGLEWOOD, Colo., Nov. 19, 2015 /PRNewswire/ -- Aytu
BioScience, Inc. (OTCQB: AYTU), a commercial-stage specialty
healthcare company focused on urological and related conditions,
today announced that the Company will host a joint conference call
with Ampio Pharmaceuticals (NYSEMKT: AMPE) to discuss the details
of Ampio's previously announced intention to distribute most of its
11,626,068 shares of Aytu to Ampio's current shareholders.
The non-dilutive share distribution constitutes greater than 70% of
the current Aytu shares outstanding, which will increase stock
liquidity substantially and further support Aytu as it operates as
an independent public company.
Josh Disbrow, Chief Executive
Officer of Aytu, stated, "We are grateful to Ampio for its
continued support and its recent decision to dramatically enhance
Aytu's capacity to achieve higher valuations by having a truly
liquid stock. This action is particularly timely, as Aytu is
positioned for substantial near-term growth through the
commercialization of our first urology products. In addition
to these products, we are looking to expand our commercial
footprint in the urology market, by seeking additional
complementary urology products that serve significant medical
needs. We look forward to providing updates on this growth
strategy and our commercial development to our newly expanded
shareholder base."
In the nine months since the Company's inception, Aytu has
acquired two revenue-generating urology products: ProstaScint, a
biologic imaging agent used by urologists to detect the extent and
spread of prostate cancer, and Primsol, a urological antibiotic. To
support these products, the Company developed its commercial
infrastructure by hiring management personnel and a urology-focused
sales force. Aytu is focused on growing revenue for these
products and seeking opportunities to acquire additional
commercial-stage assets within urology and related areas. In
parallel, the Company presented encouraging data demonstrating the
clinical utility of MiOXSYS® for measuring oxidative
stress levels in semen and is pursuing an FDA clearance pathway for
this product as a marker for male infertility. The Company
also has a therapeutic candidate, Zertane, for treating premature
ejaculation, which recently received approval from the FDA to
initiate Phase 3 studies.
Webcast/Conference Call Information:
Investor webcast link:
https://www.livemeeting.com/cc/vcc/join?id=w413596&role=attend&pw=A413596
If this link doesn't take you directly to the meeting, click on
"Accept Terms and Use Meeting Web Access," at the bottom of the
page, which will redirect you to the Webcast.
On the "Enter Meeting" page that appears, supply this
information:
- Your Name: Enter Your Name
- Meeting ID: w413596
- Entry Code: A413596
After entering this information click on "Join Meeting".
This link can also be found on the Ampio web page at:
http://www.ampiopharma.com/investors/presentations-media/
If participants wish to participate by phone for audio only,
they may use the following dial-in information.
Investor call (for audio only) information:
- U.S./Canada toll-free number:
1-888-208-1815
- International toll number: 719-457-2623
- Participant Passcode: 413596
To ask questions after the formal presentation access will be
provided through an operator for Q&A, and participants will be
instructed on how to submit questions at the time of the call.
About Aytu BioScience, Inc.
Aytu BioScience, Inc. is
a commercial-stage specialty healthcare company focused on
urological and related conditions. The Company's products includes
FDA-approved ProstaScint® (capromab pendetide), a
radio-labeled monoclonal antibody that targets Prostate Specific
Membrane Antigen (PSMA), a protein highly expressed by prostate
cancer; as well as Primsol® (trimethoprim oral
solution), the only FDA-approved oral solution of trimethoprim, the
standard therapy for urinary tract infections. Aytu's
strategy is to continue building its portfolio of
revenue-generating urology products and late-stage development
assets, leveraging its commercial team and expertise to further
build those brands within well-established markets.
For Investors & Media:
Tiberend Strategic
Advisors, Inc.
Joshua Drumm, Ph.D.:
jdrumm@tiberend.com; (212) 375-2664
Janine McCargo:
jmccargo@tiberend.com; (646) 604-5150
Forward Looking Statement
This press release includes
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, or the Exchange Act. All
statements other than statements of historical facts contained in
this presentation, including statements regarding our anticipated
future clinical and regulatory events, future financial position,
business strategy and plans and objectives of management for future
operations, are forward-looking statements. Forward looking
statements are generally written in the future tense and/or are
preceded by words such as "may," "will," "should," "forecast,"
"could," "expect," "suggest," "believe," "estimate," "continue,"
"anticipate," "intend," "plan," or similar words, or the negatives
of such terms or other variations on such terms or comparable
terminology. Such forward-looking statements include, without
limitation, statements regarding the potential future
commercialization of our product candidates, the anticipated start
dates, durations and completion dates, as well as the potential
future results, of our ongoing and future clinical trials, the
anticipated designs of our future clinical trials, anticipated
future regulatory submissions and events, our anticipated future
cash position and future events under our current and potential
future collaborations. These forward-looking statements are subject
to a number of risks, uncertainties and assumptions, including
without limitation to the risks described in "Risk Factors" in Part
I, Item 1A of Aytu BioScience, Inc. Annual Report on Form 10-K and
in the other reports and documents we file with the Securities and
Exchange Commission from time to time. These risks are not
exhaustive. Other sections of Aytu BioScience, Inc. Annual Report
on Form 10-K and such other filed reports and documents include
additional factors that could adversely impact our business and
financial performance. Moreover, we operate in a very competitive
and rapidly changing environment. New risk factors emerge from time
to time and it is not possible for our management to predict all
risk factors, nor can we assess the impact of all factors on our
business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those
contained in any forward-looking statements. You should not rely
upon forward-looking statements as predictions of future events. We
cannot assure you that the events and circumstances reflected in
the forward-looking statements will be achieved or occur and actual
results could differ materially from those projected in the
forward-looking statements. We assume no obligation to update or
supplement forward-looking statements.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/aytu-bioscience-to-benefit-from-share-distribution-by-ampio-pharmaceuticals-300181560.html
SOURCE Aytu BioScience, Inc.